All
Positive Results Reported in Roflumilast 0.15% for AD Across Diverse Populations
September 27th 2024“It is critical that our clinical data represent the diversity in the world around us, and these results further reinforce our commitment to providing meaningful innovation for immune-mediated skin diseases," said Patrick Burnett, MD, PhD, FAAD, chief medical officer of Arcutis.
Upadacitinib Demonstrates Efficacy in Patients With AD and Head and Neck Involvement
September 26th 2024Kilian Eyerich, MD, PhD, shares insights into an EADV 2024 presentation on upadacitinib’s ability to achieve almost total skin clearance in the head and neck regions with minimal effect on quality of life.
Diversifying Psoriasis Research to Benefit the Population
September 23rd 2024Zelma Chiesa Fuxench, MD, MSCE, FAAD, and Mona Shahriari, MD, FAAD, discuss the lack of research into psoriasis in skin of color, the absence of diversity in clinical trial populations, and where dermatology as a discipline can go from here.